The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Dilon Technologies said it bought RMD Instruments Corp.’s Navigator gamma probe line.
Newport News, Va.-based Dilon Technologies works with imaging technology. Watertown, Mass.-based Radiation Monitoring Devices is a research devices subsidiary of Dynasil Corp. (NSDQ:DYSL), which focuses on radiation imaging and detection.
T2 Biosystems, which is developing a diagnostic device that uses magnetic resonance technology to deliver nearly instant test results, said it raised a $40 million Series E round it plans to use for its T2Candida test for a common cause of hospital-acquired infections.
Hospital purchasing organization Novation touted 11 deals across general radiology and molecular imaging equipment, reaffirming the value that group purchasing organizations offer to vendors and health care providers.
Irving, Texas-based Novation signed one-year contracts with GE Healthcare, Siemens AG (NYSE:SI), Philips Healthcare, Fujifilm Medical Systems and a handful of others who signed on to sell radiography and molecular imaging equipment and accessories through the bulk purchaser.
Molecular imaging company Enlyton Ltd. is seeking a $3 million investment to get its cancer-detection technology into clinical studies.
The Columbus, Ohio-based company believes its targeting agent, an antibody called ATA-1, is better than the industry standard at marking cancerous tumors in medical imaging scans.
VisEn Medical Inc. acquired a 45-patent portfolio and related fluorescent imaging agent platforms from German giant Bayer Schering Pharma AG for an undisclosed amount.
The Bedford, Mass.-based imaging systems maker said it will integrate its newly acquired intellectual property into its own programs. The deal takes VisEn’s portfolio of fluorescent imaging agent patents to more than 150 worldwide.
Thermo Fisher Scientific inked a five-year distribution deal with British diagnostics maker Osmetech plc that will see the Waltham lab instruments manufacturer distribute some Osmetech products.
Fisher’s HealthCare division will sell Osmetech’s eSensor XT-8 instrument platform and molecular diagnostic tests and consumables in the United States.
The in-vitro diagnostic market, now dominated by the United States, Europe and Japan, will undergo a sea change as emerging countries take market share from the Big Three, according to a Frost & Sullivan report.
The three largest players, which owned 90 percent of the market at the end of 2007, will increasingly lose market share to such nations as India, Brazil and China in the next few years, the consulting company predicted.
